• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

EZH2通过抑制CXCL9和树突状细胞在食管鳞状细胞癌中引发CD8 T细胞耗竭。

EZH2 elicits CD8 T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells.

作者信息

Zhu Chun-Yan, Zhai Tian-Tian, Su Meng, Pan Hong-Chao, Tang Qian, Huang Bao-Hua, Chi Xin-Rui, Li Nuo, Xie Ling-Hui, Qiu Si-Qi, Pan Feng, Huang Guo-Wei

机构信息

Department of Pathology, Shantou University Medical College, Shantou, 515041, Guangdong, China.

Department of radiotherapy, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, 515041, China.

出版信息

Commun Biol. 2024 Dec 19;7(1):1645. doi: 10.1038/s42003-024-07341-9.

DOI:10.1038/s42003-024-07341-9
PMID:39702756
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11659476/
Abstract

CD8 T cell spatial distribution in the context of tumor microenvironment (TME) dictates the immunophenotypes of tumors, comprised of immune-infiltrated, immune-excluded and immune-desert, discriminating "hot" from "cold" tumors. The infiltration of cytotoxic CD8 T cells is associated with favorable therapeutic response. Hitherto, the immunophenotypes of esophageal squamous cell carcinoma (ESCC) have not yet been comprehensively delineated. Herein, we comprehensively characterized the immunophenotypes of ESCC and identified a subset of ESCC, which was defined as cold tumor and characterized with CD8 T cell-desert TME. However, the mechanism underlying the defect of CD8 T cells in TME is still pending. Herein, we uncovered that tumor cell-intrinsic EZH2 with high expression was associated with the immunophenotype of immune-desert tumors. Targeted tumor cell-intrinsic EZH2 rewired the transcriptional activation of CXCL9 mediated by NF-κB and concomitantly reinvigorated DC maturation differentiation via inducing the reduction of VEGFC secretion, thereby enhancing the infiltration of cytotoxic CD8 T cells into TME and inhibiting tumor immune evasion. Our findings identify EZH2 as a potential therapeutic target and point to avenues for targeted therapy applied to patients with ESCC characterized by CD8 T cell-desert tumors.

摘要

肿瘤微环境(TME)背景下CD8 T细胞的空间分布决定了肿瘤的免疫表型,包括免疫浸润型、免疫排斥型和免疫沙漠型,从而区分“热”肿瘤和“冷”肿瘤。细胞毒性CD8 T细胞的浸润与良好的治疗反应相关。迄今为止,食管鳞状细胞癌(ESCC)的免疫表型尚未得到全面描述。在此,我们全面表征了ESCC的免疫表型,并确定了ESCC的一个亚组,其被定义为冷肿瘤,其特征为CD8 T细胞缺失的TME。然而,TME中CD8 T细胞缺陷的潜在机制仍不明确。在此,我们发现高表达的肿瘤细胞内在EZH2与免疫沙漠型肿瘤的免疫表型相关。靶向肿瘤细胞内在EZH2可重塑由NF-κB介导的CXCL9的转录激活,并通过诱导VEGFC分泌减少,同时重振DC成熟分化,从而增强细胞毒性CD8 T细胞向TME的浸润并抑制肿瘤免疫逃逸。我们的研究结果确定EZH2为潜在的治疗靶点,并为针对以CD8 T细胞缺失肿瘤为特征的ESCC患者的靶向治疗指明了途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/701e6639f45a/42003_2024_7341_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/ba68c2f26ac3/42003_2024_7341_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/ef2f36136bc3/42003_2024_7341_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/bed5976c6729/42003_2024_7341_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/88cf329da9e4/42003_2024_7341_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/68a74e2fd21b/42003_2024_7341_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/d94cbe78de85/42003_2024_7341_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/701e6639f45a/42003_2024_7341_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/ba68c2f26ac3/42003_2024_7341_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/ef2f36136bc3/42003_2024_7341_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/bed5976c6729/42003_2024_7341_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/88cf329da9e4/42003_2024_7341_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/68a74e2fd21b/42003_2024_7341_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/d94cbe78de85/42003_2024_7341_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ea/11659476/701e6639f45a/42003_2024_7341_Fig7_HTML.jpg

相似文献

1
EZH2 elicits CD8 T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells.EZH2通过抑制CXCL9和树突状细胞在食管鳞状细胞癌中引发CD8 T细胞耗竭。
Commun Biol. 2024 Dec 19;7(1):1645. doi: 10.1038/s42003-024-07341-9.
2
Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma.程序性死亡受体 1 配体(PD-L1)抑制剂与放疗联合应用对食管鳞状细胞癌小鼠模型肿瘤免疫微环境的影响
BMC Cancer. 2025 Mar 14;25(1):474. doi: 10.1186/s12885-025-13801-0.
3
LINC00152 mediates CD8 T-cell infiltration in gastric cancer through binding to EZH2 and regulating the CXCL9, 10/CXCR3 axis.LINC00152 通过与 EZH2 结合并调节 CXCL9、10/CXCR3 轴来介导胃癌中的 CD8 T 细胞浸润。
J Mol Histol. 2021 Jun;52(3):611-620. doi: 10.1007/s10735-021-09967-z. Epub 2021 Mar 11.
4
SUMO modified ETV1 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by facilitating CCL2 transcription in esophageal squamous cell carcinoma cells.SUMO修饰的ETV1通过促进食管鳞状细胞癌细胞中CCL2的转录,促进M2极化的肿瘤相关巨噬细胞浸润和癌症进展。
Cancer Immunol Immunother. 2025 Feb 1;74(3):87. doi: 10.1007/s00262-024-03914-z.
5
Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment.人类食管鳞状细胞癌微环境中的免疫抑制景观。
Nat Commun. 2020 Dec 8;11(1):6268. doi: 10.1038/s41467-020-20019-0.
6
NME4 suppresses NFκB2-CCL5 axis, restricting CD8+ T cell tumour infiltration in oesophageal squamous cell carcinoma.NME4 抑制 NFκB2-CCL5 轴,限制食管鳞状细胞癌中 CD8+T 细胞的肿瘤浸润。
Immunology. 2024 Oct;173(2):408-421. doi: 10.1111/imm.13838. Epub 2024 Jul 17.
7
CircNF1 modulates the progression and immune evasion of esophageal squamous cell carcinoma through dual regulation of PD-L1.环状核纤层蛋白1(CircNF1)通过对程序性死亡受体配体1(PD-L1)的双重调控来调节食管鳞状细胞癌的进展和免疫逃逸。
Cell Mol Biol Lett. 2025 Mar 29;30(1):37. doi: 10.1186/s11658-025-00712-y.
8
Characterization of CD103 CD8 tissue-resident T cells in esophageal squamous cell carcinoma: may be tumor reactive and resurrected by anti-PD-1 blockade.CD103+CD8+ 食管鳞状细胞癌组织驻留 T 细胞的特征:可能是肿瘤反应性的,并可被抗 PD-1 阻断剂复活。
Cancer Immunol Immunother. 2020 Aug;69(8):1493-1504. doi: 10.1007/s00262-020-02562-3. Epub 2020 Apr 13.
9
CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.CCL2-CCR2 轴通过 PD-1 信号招募肿瘤相关巨噬细胞诱导免疫逃逸在食管癌变中。
Mol Cancer. 2020 Feb 27;19(1):41. doi: 10.1186/s12943-020-01165-x.
10
FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma.FOXO1 通过增加食管鳞状细胞癌中的 M2 巨噬细胞浸润促进肿瘤进展。
Theranostics. 2020 Sep 16;10(25):11535-11548. doi: 10.7150/thno.45261. eCollection 2020.

引用本文的文献

1
Constitutive expression of the transcriptional co-activator IκBζ promotes melanoma growth and immunotherapy resistance.转录共激活因子IκBζ的组成型表达促进黑色素瘤生长和免疫治疗抗性。
Nat Commun. 2025 Jun 25;16(1):5387. doi: 10.1038/s41467-025-60929-5.
2
Cross-Talk Between Cancer and Its Cellular Environment-A Role in Cancer Progression.癌症与其细胞微环境之间的相互作用——在癌症进展中的作用
Cells. 2025 Mar 10;14(6):403. doi: 10.3390/cells14060403.
3
Nanovaccines empowering CD8 T cells: a precision strategy to enhance cancer immunotherapy.

本文引用的文献

1
HIF-1α Mediates Immunosuppression and Chemoresistance in Colorectal Cancer by Inhibiting CXCL9, -10 and -11.HIF-1α 通过抑制 CXCL9、-10 和 -11 介导结直肠癌中的免疫抑制和化疗耐药。
Biomed Pharmacother. 2024 Apr;173:116427. doi: 10.1016/j.biopha.2024.116427. Epub 2024 Mar 13.
2
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.在局部晚期可切除食管鳞癌中的新辅助 adebrelimab:1b 期试验。
Nat Med. 2023 Aug;29(8):2068-2078. doi: 10.1038/s41591-023-02469-3. Epub 2023 Jul 24.
3
Spatial analysis of stromal signatures identifies invasive front carcinoma-associated fibroblasts as suppressors of anti-tumor immune response in esophageal cancer.
纳米疫苗增强CD8 T细胞:一种增强癌症免疫疗法的精准策略。
Theranostics. 2025 Feb 10;15(7):3098-3121. doi: 10.7150/thno.107856. eCollection 2025.
肿瘤微环境特征的空间分析鉴定出浸润前缘癌相关成纤维细胞是食管癌抗肿瘤免疫反应的抑制因子。
J Exp Clin Cancer Res. 2023 May 31;42(1):136. doi: 10.1186/s13046-023-02697-y.
4
EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.EZH2 介导的代谢重编程促进卵巢癌肿瘤生长,而不依赖于组蛋白甲基转移酶活性。
Mol Cancer. 2023 May 20;22(1):85. doi: 10.1186/s12943-023-01786-y.
5
Tumor‑infiltrating CD8 T cells as a biomarker for chemotherapy efficacy in unresectable hepatocellular carcinoma.肿瘤浸润性CD8 T细胞作为不可切除肝细胞癌化疗疗效的生物标志物
Oncol Lett. 2023 Apr 28;25(6):259. doi: 10.3892/ol.2023.13845. eCollection 2023 Jun.
6
Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment.食管鳞状细胞癌中的免疫逃逸:从肿瘤微环境的角度来看
Front Oncol. 2023 Jan 9;12:1096717. doi: 10.3389/fonc.2022.1096717. eCollection 2022.
7
CXCL9 and CXCL10 bring the heat to tumors.CXCL9 和 CXCL10 为肿瘤带来炎症反应。
Sci Immunol. 2022 Jul 22;7(73):eabq6509. doi: 10.1126/sciimmunol.abq6509.
8
Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets.食管癌新的免疫检查点:从生物标志物到治疗靶点。
Front Immunol. 2022 May 20;13:864202. doi: 10.3389/fimmu.2022.864202. eCollection 2022.
9
Ezh2 competes with p53 to license lncRNA Neat1 transcription for inflammasome activation.Ezh2 与 p53 竞争,为 lncRNA Neat1 的转录赋予许可证,从而激活炎症小体。
Cell Death Differ. 2022 Oct;29(10):2009-2023. doi: 10.1038/s41418-022-00992-3. Epub 2022 May 14.
10
EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis.EZH2 通过一个隐藏的反式激活结构域非canonically 结合 cMyc 和 p300,以介导基因激活并促进肿瘤发生。
Nat Cell Biol. 2022 Mar;24(3):384-399. doi: 10.1038/s41556-022-00850-x. Epub 2022 Feb 24.